MX2019008921A - Adenovirus recombinante de transgenes múltiples. - Google Patents
Adenovirus recombinante de transgenes múltiples.Info
- Publication number
- MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- multiple transgene
- transgene recombinant
- insertion site
- transgenes
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452342P | 2017-01-30 | 2017-01-30 | |
| US201762520945P | 2017-06-16 | 2017-06-16 | |
| PCT/US2018/016032 WO2018140973A1 (en) | 2017-01-30 | 2018-01-30 | Multiple transgene recombinant adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008921A true MX2019008921A (es) | 2019-11-08 |
Family
ID=62978741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008921A MX2019008921A (es) | 2017-01-30 | 2018-01-30 | Adenovirus recombinante de transgenes múltiples. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190352616A1 (enExample) |
| EP (1) | EP3574090A4 (enExample) |
| JP (1) | JP2020505049A (enExample) |
| KR (1) | KR20190128634A (enExample) |
| CN (1) | CN110741080A (enExample) |
| AU (1) | AU2018213417A1 (enExample) |
| BR (1) | BR112019015600A2 (enExample) |
| CA (1) | CA3052090A1 (enExample) |
| IL (1) | IL268291A (enExample) |
| MX (1) | MX2019008921A (enExample) |
| SG (1) | SG11201906973TA (enExample) |
| WO (1) | WO2018140973A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| CA3064892A1 (en) * | 2017-05-24 | 2018-11-29 | Epicentrx, Inc. | Anti-angiogenic adenovirus |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
| EP4349975A4 (en) * | 2021-05-25 | 2025-04-16 | Voncolytic Therapeutics Co., Ltd. | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment |
| CN113249342B (zh) * | 2021-05-25 | 2023-12-01 | 江苏万戎生物医药科技有限公司 | 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| HUE046565T2 (hu) * | 2009-03-02 | 2020-03-30 | Univ California | Tumorszelektív adenovírus E1A és E1B mutánsok |
| US20130195800A1 (en) * | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
| BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| US11155599B2 (en) * | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| DK3461491T3 (da) * | 2013-04-18 | 2025-02-03 | Tilt Biotherapeutics Oy | Forbedret adoptiv celleterapi |
| CN103614416B (zh) * | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
| PL3198009T3 (pl) * | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-01-30 US US16/482,055 patent/US20190352616A1/en not_active Abandoned
- 2018-01-30 AU AU2018213417A patent/AU2018213417A1/en not_active Abandoned
- 2018-01-30 CA CA3052090A patent/CA3052090A1/en active Pending
- 2018-01-30 CN CN201880021787.6A patent/CN110741080A/zh active Pending
- 2018-01-30 EP EP18743942.7A patent/EP3574090A4/en not_active Withdrawn
- 2018-01-30 BR BR112019015600-3A patent/BR112019015600A2/pt not_active Application Discontinuation
- 2018-01-30 SG SG11201906973TA patent/SG11201906973TA/en unknown
- 2018-01-30 MX MX2019008921A patent/MX2019008921A/es unknown
- 2018-01-30 WO PCT/US2018/016032 patent/WO2018140973A1/en not_active Ceased
- 2018-01-30 KR KR1020197025498A patent/KR20190128634A/ko not_active Ceased
- 2018-01-30 JP JP2019541188A patent/JP2020505049A/ja active Pending
-
2019
- 2019-07-28 IL IL268291A patent/IL268291A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201906973TA (en) | 2019-08-27 |
| EP3574090A1 (en) | 2019-12-04 |
| US20190352616A1 (en) | 2019-11-21 |
| JP2020505049A (ja) | 2020-02-20 |
| EP3574090A4 (en) | 2021-01-06 |
| BR112019015600A2 (pt) | 2020-03-17 |
| AU2018213417A1 (en) | 2019-08-15 |
| CA3052090A1 (en) | 2018-08-02 |
| KR20190128634A (ko) | 2019-11-18 |
| WO2018140973A1 (en) | 2018-08-02 |
| IL268291A (en) | 2019-09-26 |
| CN110741080A (zh) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
| SG11202111149VA (en) | Plasmid system | |
| MX2025014378A (es) | Composiciones utiles para la edicion del gen ttr y el tratamiento de la amiloidosis attr | |
| PH12021550843A1 (en) | Nucleic acid constructs and methods of use | |
| SG11202103314QA (en) | Engineered genetic modulators | |
| IL284742A (en) | AAV-mediated gene therapy restoring the autoperlin gene | |
| EP4555965A3 (en) | Robotic surgical devices, systems and related methods | |
| IL268291A (en) | Multiple transgene recombinant adenovirus | |
| LT3722434T (lt) | Plazmidžių sistema | |
| SG11202000650YA (en) | Factor viii (fviii) gene therapy methods | |
| GB201805567D0 (en) | Implant alignment system | |
| IL286466A (en) | Systems and methods for phenotypic gardening | |
| GB201905301D0 (en) | Gene therapy | |
| SG11202012978VA (en) | Gene therapy | |
| MX2018000984A (es) | Terapias de combinacion. | |
| GB201819426D0 (en) | Implant assembly and associated methods | |
| GB201802326D0 (en) | Gene therapy | |
| EP3847259A4 (en) | VTVAF17 VECTOR-BASED GENE THERAPY | |
| SG11202006740QA (en) | Gaming system | |
| GB201817470D0 (en) | Gene therapy | |
| EP3548036A4 (en) | NATURAL COMBINATION HORMONE REPLACEMENT FORMULAS AND THERAPIES | |
| ZA202007857B (en) | Gaming system | |
| GB201816955D0 (en) | Augumented reality system | |
| EA201991805A1 (ru) | Множественно трансгенный рекомбинантный аденовирус | |
| Disney | Mahasi Sasana Yeiktha (six sijo/stlings) |